Home » Stocks » REGN

Regeneron Pharmaceuticals, Inc. (REGN)

Stock Price: $453.00 USD -5.61 (-1.22%)
Updated Feb 25, 2021 3:59 PM EST - Market closed
After-hours: $455.26 +2.27 (0.50%) Feb 25, 4:27 PM
Market Cap 49.13B
Revenue (ttm) 8.50B
Net Income (ttm) 3.51B
Shares Out 107.60M
EPS (ttm) 30.52
PE Ratio 14.84
Forward PE 10.46
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $453.00
Previous Close $458.60
Change ($) -5.61
Change (%) -1.22%
Day's Open 460.31
Day's Range 448.33 - 465.00
Day's Volume 1,124,791
52-Week Range 418.01 - 664.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 days ago

The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.

Other stocks mentioned: BNTX, JNJ, LLY, MRNA, PFE
Benzinga - 2 days ago

The FDA approved expanded use of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi's SA (NASDAQ: SNY) immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced l...

Other stocks mentioned: SNY
The Motley Fool - 2 days ago

This latest pick has been sluggish so far -- but the long-term opportunity may be huge.

GlobeNewsWire - 3 days ago

FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

PRNewsWire - 1 week ago

TARRYTOWN, N.Y., Feb. 12, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: SVB Leerink 10th Annual Global Healthcare Confer...

Investors Business Daily - 1 week ago

Hijacking the immune system to destroy cancer with bispecific antibodies could be a lucrative business for biotech stocks like Amgen, Genmab and Regeneron Pharmaceuticals. The post The $12 Bil...

Other stocks mentioned: AMGN, GMAB
PRNewsWire - 1 week ago

TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ -- Upholds decision by U.S. District Court to invalidate Amgen's patent claims directed to PCSK9 antibodies Regeneron Pharmaceuticals, Inc. (NASDAQ:...

The Motley Fool - 2 weeks ago

These stocks would be buys even without the pandemic.

Other stocks mentioned: EBS, PFE
Zacks Investment Research - 2 weeks ago

The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.

Other stocks mentioned: SNY
The Motley Fool - 2 weeks ago

These biotechs are developing innovative therapies while doing their part to combat the coronavirus.

Other stocks mentioned: GILD, JNJ
Benzinga - 2 weeks ago

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell car...

Other stocks mentioned: SNY
InvestorPlace - 2 weeks ago

Investors are enamored with high profile stocks and ignoring ones that are solid investments. Here are three biotech stocks to consider.

Other stocks mentioned: MRK, PFE
InvestorPlace - 2 weeks ago

Ford, Clorox, Regeneron and Luckin Coffee were our top stock trades for Monday. Let's get a look at the charts as we head into next week.

Other stocks mentioned: F, CLX, LKNCY
Invezz - 2 weeks ago

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) said on Friday that its profit came in better than expected in the fiscal fourth quarter. Revenue, it added, matched forecasts in Q4.

Zacks Investment Research - 2 weeks ago

Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.

The Motley Fool - 2 weeks ago

The big biotech was firing on all cylinders, and getting strong growth out of its top-selling products.

Schaeffers Research - 2 weeks ago

The shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are up 2.3% to trade at $510.38 this morning, after the company reported better-than-expected fourth-quarter earnings of $9.53 per sha...

Zacks Investment Research - 2 weeks ago

Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 1.45%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 weeks ago

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported fourth-quarter earnings of $9.53 per share, which beat the analyst consensus estimate of $8.39. Quarterly sales of $2.42 billion increased...

Benzinga - 2 weeks ago

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 2.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 27.07% year ove...

PRNewsWire - 2 weeks ago

TARRYTOWN, N.Y., Feb. 5, 2021 /PRNewswire/ -- Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019(4) Fourth quarter 2020 EYLEA® U.S. net sales increased 10% ...

Benzinga - 3 weeks ago

On Friday, February 05, Regeneron Pharmaceuticals (NASDAQ:REGN) will release its latest earnings report. Benzinga's outlook for Regeneron Pharmaceuticals is included in the following report.

InvestorPlace - 3 weeks ago

Investing in stocks that show long-term potential is a tried and true way to earn some long-term gains. Here's a look at seven growth stocks worth buying this year.

Other stocks mentioned: DIS, NKE, PTON, ROKU, SQ, VRM
Zacks Investment Research - 3 weeks ago

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports fourth-quarter 2020 results.

Zacks Investment Research - 3 weeks ago

In the latest trading session, Regeneron (REGN) closed at $508.08, marking a +0.84% move from the previous day.

24/7 Wall Street - 3 weeks ago

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Other stocks mentioned: AMGN, BIIB, GILD, MRK, PFE, ABBV, ALXN, BMY
The Motley Fool - 3 weeks ago

There's some good news and some bad news.

Other stocks mentioned: LLY
Zacks Investment Research - 4 weeks ago

Regeneron (REGN) reports research data confirming that antibody REGEN-COV is effective against the SARS-CoV-2 variants.

The Motley Fool - 4 weeks ago

Strong interim trial data boosts the prospects for a treatment already worth billions.

The Motley Fool - 4 weeks ago

Roku and Regeneron are poised to be top-notch growth picks.

Other stocks mentioned: ROKU
Zacks Investment Research - 4 weeks ago

Regeneron (REGN) reports positive initial results from a phase III study evaluating REGEN-COV antibody cocktail as a passive vaccine for the prevention of people at high risk of COVID-19 infec...

Market Watch - 4 weeks ago

Shares of Regeneron Pharmaceuticals Inc. gained 1.2% in premarket trading on Wednesday after the company said its COVID-19 antibody cocktail still works against two new more infectious strains...

CNBC Television - 4 weeks ago

Regeneron antibody cocktail works against UK and South African variants, study finds

Regeneron has released research on the company's coronavirus antibody cocktail that found the cocktail retains its potency against the U.K. and South African variants of the virus. The study w...

PRNewsWire - 4 weeks ago

TARRYTOWN, N.Y., Jan. 27, 2021 /PRNewswire/ -- Columbia University researchers and Regeneron have independently confirmed findings; data included in bioRxiv paper and submitted for peer-review...

Zacks Investment Research - 4 weeks ago

Regeneron (REGN) closed at $544.10 in the latest trading session, marking a -0.75% move from the prior day.

Zacks Investment Research - 4 weeks ago

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and position it for growth in 2021.

Market Watch - 4 weeks ago

Shares of Regeneron Pharmaceuticals Inc. were up 1.8% in premarket trading on Tuesday after the company said its COVID-19 antibody cocktail can prevent people at high risk of a COVID-19 infect...

CNBC Television - 4 weeks ago

Regeneron antibody drug shown to prevent symptomatic Covid-19

Regeneron reported Tuesday that its antibody cocktail for coronavirus has show a reduction in overall infections seen within the first week, with 100% prevention of symptomatic infections. CNB...

Benzinga - 1 month ago

AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister also said he expects the EU to approve th...

Other stocks mentioned: AUPH, AZN, CNST
Seeking Alpha - 1 month ago

REGN reached a $2.6 billion COVID-19 supply deal with the government. The recent deal could have a sizeable impact on REGN's revenue and EBITDA. The question remains, "How much is recurring?"

PRNewsWire - 1 month ago

TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in the Regeneron Sci...

PRNewsWire - 1 month ago

TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2021 /PRNewswire/ -- Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. STEM Competition for High School Seniors Over ...

PRNewsWire - 1 month ago

TARRYTOWN, N.Y., Jan. 19, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2020 financial and operating ...

Zacks Investment Research - 1 month ago

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Motley Fool - 1 month ago

This high-growing, blue-chip biotech has just what it takes to make investors rich.

InvestorPlace - 1 month ago

Amazon, Plug Power, GameStop and Regeneron were our top stock trades for Thursday. Let's have a look at the charts after some big moves.

Other stocks mentioned: AMZN, GME, PLUG
Zacks Investment Research - 1 month ago

Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.

Benzinga - 1 month ago

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringin...

Other stocks mentioned: JAGX, SNCA
The Motley Fool - 1 month ago

Rapid expansion beyond the Eylea franchise is causing analysts to raise their ratings on the big biotech.

Benzinga - 1 month ago

Biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the signing of a $2.625 billion supply agreement with the U.S. government for its COVID-19 antibody cocktail. What Happen...

About REGN

Regeneron Pharmaceuticals discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injecti... [Read more...]

Industry
Biotechnology
IPO Date
Apr 2, 1991
CEO
Leonard Schleifer
Employees
9,123
Stock Exchange
NASDAQ
Ticker Symbol
REGN
Full Company Profile

Financial Performance

In 2020, REGN's revenue was $8.50 billion, an increase of 29.58% compared to the previous year's $6.56 billion. Earnings were $3.51 billion, an increase of 66.05%.

Financial Statements

Analyst Forecasts

According to 27 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is 650.83, which is an increase of 43.67% from the latest price.

Price Target
$650.83
(43.67% upside)
Analyst Consensus: Buy